A randomized double-blind controlled trial of naftidrofuryl in acute stroke.
There is evidence to support the use of naftidrofuryl in acute stroke with claims of increased recovery, reduced fatality and reduced bed occupancy in patients treated with either oral or intravenous preparations. One hundred patients presenting with acute hemisphere stroke (less than 72 hours) were randomized to receive either a new oral formulation of naftidrofuryl or placebo on a double-blind basis. Treatment was given for a total of 12 weeks and patients followed for 26 weeks with serial neurological and functional assessments by a single observer. Cumulative fatality and hospital-bed occupancy were determined at each assessment interval. No significant difference was demonstrated in cumulative fatality, hospital-bed occupancy or recovery of motor function in patients treated with either naftidrofuryl or placebo. There is no evidence from this study to support the use of oral naftidrofuryl in acute stroke.
Gray
C S
CS
Department of Geriatrics, City Hospital, Edinburgh.
French
J M
JM
Venables
G S
GS
Cartlidge
N E
NE
James
O F
OF
Bates
D
D
D000208:Acute Disease; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000503:physiopathology; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009257:Nafronyl / Q000009:adverse effects / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D009257:Nafronyl